Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The cardiovascular effects of ertugliflozin, an inhibitor of sodium-glucose cotransporter 2, have not been established. METHODS: In a multicenter, double-blind trial, we randomly assigned patients with type 2 diabetes and atherosclerotic cardiovascular disease to receive 5 mg or 15 mg of ertugliflozin or placebo once daily. With the data from the two ertugliflozin dose groups pooled for analysis, the primary objective was to show the noninferiority of ertugliflozin to placebo with respect to the primary outcome, major adverse cardiovascular events (a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke). The noninferiority margin was 1.3 (upper boundary of a 95.6% confidence interval for the hazard ratio [ertugliflozin vs. placebo] for major adverse cardiovascular events). The first key secondary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure. RESULTS: A total of 8246 patients underwent randomization and were followed for a mean of 3.5 years. Among 8238 patients who received at least one dose of ertugliflozin or placebo, a major adverse cardiovascular event occurred in 653 of 5493 patients (11.9%) in the ertugliflozin group and in 327 of 2745 patients (11.9%) in the placebo group (hazard ratio, 0.97; 95.6% confidence interval [CI], 0.85 to 1.11; P<0.001 for noninferiority). Death from cardiovascular causes or hospitalization for heart failure occurred in 444 of 5499 patients (8.1%) in the ertugliflozin group and in 250 of 2747 patients (9.1%) in the placebo group (hazard ratio, 0.88; 95.8% CI, 0.75 to 1.03; P = 0.11 for superiority). The hazard ratio for death from cardiovascular causes was 0.92 (95.8% CI, 0.77 to 1.11), and the hazard ratio for death from renal causes, renal replacement therapy, or doubling of the serum creatinine level was 0.81 (95.8% CI, 0.63 to 1.04). Amputations were performed in 54 patients (2.0%) who received the 5-mg dose of ertugliflozin and in 57 patients (2.1%) who received the 15-mg dose, as compared with 45 patients (1.6%) who received placebo. CONCLUSIONS: Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, ertugliflozin was noninferior to placebo with respect to major adverse cardiovascular events. (Funded by Merck Sharp & Dohme and Pfizer; VERTIS CV ClinicalTrials.gov number, NCT01986881.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The trial of once-weekly exenatide demonstrated a directionally favorable effect on MACE but narrowly missed statistical significance.644”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [644]
In the citing paper
“In the CVOTs Harmony Outcomes (albiglutide vs placebo), EXSCEL (exenatide LA vs placebo), and AMPLITUDE-O (efpeglenatide vs placebo), there were numerically fewer strokes, but HRs were not significant.472,641,644”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [644]
In the citing paper
“The SGLT2i cardiovascular outcome trials (CVOTs) have reported DKA rates of 0.1 -0.6% compared with rates of < 0.1 -0.3% with placebo (143 -147), with very low rates in the HF (148 -151) and CKD (152,153) outcome studies.”
In the citing paper
“In the Evaluation of Ertugli fl ozin Ef fi cacy and Safety CVOT (VERTIS CV), which recruited exclusively people with established CVD and type 2 diabetes, ertugli fl ozin was similar to placebo with respect to the primary MACE outcome and all key secondary outcomes (including a composite kidney outcome) except for HHF (146).”
In the citing paper
“While there was a trend for bene fi t for the key secondary endpoint of cardiovascular death or heart failure hospitalization, this did not meet statistical signi fi cance (HR: 0.88; 95% CI: 0.75 -1.03).”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [91]
18 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Self-citationCanagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationEmpagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Mortality and cardiovascular disease in type 1 and type 2 diabetes
Rawshani, A., Rawshani, A., Franzén, S., Eliasson, B., Svensson, A.-M., Miftaraj, M., McGuire, D. K., Sattar, N., Rosengren, A., & Gudbjörnsdottir, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608664 · Cited by 1,389
Self-citationKDOQI clinical practice guideline for diabetes and CKD: 2012 update
(2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.005 · Cited by 1,320
Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease
Thomas, M. C., Cooper, M. E., & Zimmet, P. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.173 · Cited by 742
Interim analysis: The alpha spending function approach
Demets, D. L., & Lan, K. K. G. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131308 · Cited by 564
Cannon, C. P., McGuire, D. K., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Charbonnel, B., Shih, W. J., Gallo, S., Masiukiewicz, U., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.08.016 · Cited by 203
Self-citation
Research works printed but not linked: 1
- Food and Drug Administration. Guidance for industry: diabetes mellitus — evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Fed Regist 2008;73(245):77724-77725 (https://www.govinfo.gov/content/pkg/FR-2008-12-19/pdf/E8-30086.pdf).
Cited by
Items 901–1,000 of 1,001
Intersection Between Diabetes and Heart Failure: Is SGLT2i the “One Stone for Two Birds” Approach?
Zhang, Q., Kang, Y., Tang, S., & Yu, C. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01591-3 · Cited by 6
Rivera, P., Rodríguez-Zúñiga, M. J. M., Caballero-Alvarado, J., & Fiestas, F. (2021) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462321001689 · Cited by 10
The anti-hypertensive effects of sodium-glucose cotransporter-2 inhibitors
Kugathasan, L., Dubrofsky, L., Advani, A., & Cherney, D. Z. I. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2159810 · Cited by 5
“Like the CANVAS program, the VERTIS CV (Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes) Trial [16,19] also reported a 3.”
BackgroundMethodSelf-citationNewer Glucose-Lowering Therapies in Older Adults with Type 2 Diabetes
Bilal, A., & Pratley, R. E. (2023) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.10.010 · Cited by 5
Self-citationCheng, Q., Zou, S., Feng, C., Xu, C., Zhao, Y., Shi, X., & Sun, M. (2023) · Medicine · doi:10.1097/md.0000000000033198 · Cited by 6
Muller, N., Busch, M., Gerdes, C., & Wolf, G. (2023) · Nephrologie aktuell · doi:10.1055/a-2055-3322 · Cited by 5
Canagliflozin + metformin ER for the treatment of type 2 diabetes: the evidence to date
Tomlinson, B., & Li, Y. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2276180 · Cited by 6
“Ertugliflozin also reduced hospitalization for heart failure but not overall major adverse cardiovascular events In the VERTIS CV cardiovascular outcome trial [20].”
BackgroundKim, J. H., Lyu, Y. S., Kim, B., Kim, M. K., Kim, S. Y., Baek, K., Song, K., Han, K., & Kwon, H. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15565 · Cited by 5
“10 11 – 17 To date, only one large population-based report has explored the effect of SGLT2 inhibitors limited only in this group.”
BackgroundThe role of sodium glucose co-transporter inhibitors in heart failure prevention
Garla, V. V., Subauste, A. R., Butler, J., & Lien, L. F. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107811 · Cited by 5
Vlasschaert, C., Sidhu, B., & Silver, S. A. (2021) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000703 · Cited by 5
Qiu, M., Ding, L., & Zhou, H. (2021) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-20-984 · Cited by 6
“Moreover, different CVOTs reported the inconsistent results as for the identical subgroup.”
MethodResultInfluentialDelivering joined-up care for people with type 2 diabetes: rationale, challenges and examples
Bain, S. C., Rickford, A., Black, N., Hamilton, L., Camfield, E., Chamley, M., Hodgkinson, A., & Karalliedde, J. J. (2021) · British Journal of Diabetes · doi:10.15277/bjd.2021.294 · Cited by 5
Treating heart failure in patients with diabetes: The view of the cardiologist
Kumowski, N., Marx, N., & Schütt, K. S. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108852 · Cited by 5
Ertugliflozin + metformin as a treatment option for type 2 diabetes
Athyros, V. G., Boutari, C., & Karagiannis, A. I. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1939676 · Cited by 5
Gronda, E., Napoli, C., Iacoviello, M., Urbinati, S., Caldarola, P., Mannucci, E., Colivicchi, F., & Gabrielli, D. (2021) · European Heart Journal Supplements · doi:10.1093/eurheartj/suab066 · Cited by 5
“Some caution may concern ertugliflozin for which a single large study did not provide significant results on mortality and major cardiovascular events, but only on hospitalizations for heart failure.(11)”
BackgroundSGLT-2 Inhibitor Use in Heart Failure: A Review for Nurses
March, K. L., Lukas, J. G., Berei, T. J., Shah, S. P., & Cave, B. E. (2022) · Critical Care Nursing Quarterly · doi:10.1097/cnq.0000000000000401 · Cited by 7
McRae, M., & Wang, C. C. L. (2022) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2021.11.012 · Cited by 8
Chan, Y., Stickland, N., & Stewart, S. (2022) · European Journal of Cardiovascular Nursing · doi:10.1093/eurjcn/zvac036 · Cited by 5
Evans, M., Berry, S., Nazeri, A., Malkin, S. J. P., Ashley, D., Hunt, B., & Bain, S. C. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14917 · Cited by 5
Ghosal, S., Sinha, B., & Mukherjee, R. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14296 · Cited by 5
Patorno, E., Htoo, P. T., Everett, B. M., & Kim, S. C. (2022) · Annals of Internal Medicine · doi:10.7326/l21-0708 · Cited by 5
SGLT2 Inhibitors and Diabetes: Where Does It Come from and Where Does It Go?
Kim, J. Y., & Kim, S. G. (2024) · Journal of Korean Diabetes · doi:10.4093/jkd.2024.25.1.9 · Cited by 4
Karagiannidis, A. G., Theodorakopoulou, M. P., Alexandrou, M. E., Iatridi, F., Karkamani, E., Anastasiou, V., Mykoniatis, I., Kamperidis, V., Strippoli, G. F., & Sarafidis, P. A. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14335 · Cited by 7
Shi, S., Li, X., Chen, Y., Li, J., & Dai, Y. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70044 · Cited by 5
Pathan, M. F., Akter, N., Mustari, M., Saifuddin, M., Sharifuzzaman, M., Rahman, M. M., Ripon, M., Mohiuddin, S. M., Kamrul-Hasan, A. B. M., Hannan, M. A., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1542946 · Cited by 7
Oda, Y., Nishi, H., Sekiguchi, M., Odawara, M., & Nangaku, M. (2025) · Kidney Diseases · doi:10.1159/000545626 · Cited by 4
SGLT2 inhibition mitigates intracerebral hemorrhage risk by modulating inflammation
Huang, M., Liu, Y., & Chen, C. (2025) · Scientific Reports · doi:10.1038/s41598-024-84118-4 · Cited by 5
Cardiovascular complications in Diabetes: The role of NLRP3 inflammasome and targeted interventions
Jeyaraj, G. (2025) · Obesity Medicine · doi:10.1016/j.obmed.2025.100629 · Cited by 4
Parveen, A., Parveen, S., Vats, N., Shafeeque, M., Choudhary, A., Zaidi, S. A. H., & Yar, M. S. (2025) · Archiv der Pharmazie · doi:10.1002/ardp.70127 · Cited by 4
“• Ertugliflozin, in the VERTIS ‐ CV trial, showed non ‐ inferiority in MACE reduction but favorable glycemic and renal profiles [124].”
Ortiz-Seller, A., Ortiz-Seller, D., Morcillo, E. J., & Ortiz, J. L. (2025) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-025-02071-2 · Cited by 4
Al-Qurain, A. A., Salem, M., Algarzai, B. A., Eljadi, E. M., Elsayed, H., Almuhanna, A., Albuhayji, D. S., Salami, M., Alzahrani, J. A., Alsayyali, J., et al. (2026) · Cureus · doi:10.7759/cureus.100927 · Cited by 7
“The SGLT2i node comprises data from six trials: EMPA-REG OUTCOME [26], CANVAS Program [27], DECLARE-TIMI 58 [28], VERTIS CV [29], CREDENCE [30], and SCORED [31].”
Influential2026 ACC/AHA Clinical Performance and Quality Measures for Patients With Peripheral Artery Disease
Goodney, P. P., Ross, E., Bruckel, J. T., Alabi, O., Altin, S. E., Bauer, K. L., Diekemper, R. L., Gerhard‐Herman, M. D., Johnston, L. E., Martin, V. T., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.09.003 · Cited by 4
Mechanistic Links Between the Gut Microbiome and Longevity Therapeutics
Garzon-Escamilla, N., Medina-Cardena, M., Roy, P., Trent, J., Jamous, J., Somesan, Y., & Denslow, S. (2026) · Biomedicines · doi:10.3390/biomedicines14020316 · Cited by 7
Seidu, S., Kunutsor, S. K., Taguiam, E., & Khunti, K. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70728 · Cited by 4
Zhang, X., Zhang, Y., & Hu, Y. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1039348 · Cited by 6
Kim, J. M., Bhatt, D. L., Dagogo-Jack, S. E., Cherney, D. Z. I., Cosentino, F., McGuire, D. K., Pratley, R. E., Liu, C., Cater, N. B., Frederich, R. C., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14965 · Cited by 4
“During VERTIS CV, participants with T2D and established ASCVD were enrolled across 34 countries.(8) Full eligibility criteria for VERTIS CV were reported previously, including a requirement for the dose of any lipid-modifying medication to be stable for at least 4 weeks, and the exclusion of participants with fasting…”
MethodSelf-citationMuschitz, C., Kautzky‐Willer, A., Winhofer, Y., Rauner, M., Haschka, J., Cejka, D., Wakolbinger, R., & Pietschmann, P. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-022-02118-8 · Cited by 4
Huang, C., & Lee, J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051387 · Cited by 4
“A substantial A substantial body of evidence has shown positive cardiovascular [19–22] and renal outcomes [23–26] associated with the use of SGLT2is in T2DM, although many of these studies primarily involved participants taking metformin at the baseline. body of evidence has shown positive…”
BackgroundResultInfluentialHoda, F., Jamali, M. C., Arshad, M., Habib, M. A., Akhtar, M., & Najmi, A. K. (2024) · Drug Research · doi:10.1055/a-2366-8999 · Cited by 5
“Canagliflozin dem - onstrated similar benefits in the CANVAS program, while dapagli - flozin showed positive outcomes in the DECLARE-TIMI trial [23].”
Hsiao, Y.-Y., Chen, Y., Kuo, M., Chien, Y.-S., Li, G., Wu, S., Lin, W.-L., Chiu, S.-F., Li, C.-H., Lin, J.-C., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae861 · Cited by 4
Antidiabetic combination therapy and cardiovascular outcomes: An evidence-based approach
Ganakumar, V., Fernandez, C. J., & Pappachan, J. M. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i4.102390 · Cited by 4
Bhagya, G., Namini, M. T., Girish, B. S., & Srinivasan, R. (2025) · Prospects in Pharmaceutical Sciences · doi:10.56782/pps.274 · Cited by 6
“In patients with T2DM and atherosclerotic cardiovascular disease, ertugliflozin was found to be noninferior to placebo for major adverse cardiovascular events [72].”
Pagel, P. S., Hang, D., Freed, J. K., & Crystal, G. J. (2025) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2025.05.010 · Cited by 6
Ghouri, N., Javed, H., & Sattar, N. A. (2020) · Current Diabetes Reviews · doi:10.2174/1573399817666201228120725 · Cited by 6
Berg, D. D., Kolkailah, A. A., Sarraju, A., Kerchberger, A. M., Eljalby, M., & McGuire, D. K. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01417-0 · Cited by 4
Self-citationVider, E., Sapir, R., Mosseri, E., & Gavioli, E. M. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001176 · Cited by 4
Narcisse, D. I., Katzenberger, D. R., & Gutierrez, J. A. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01677-6 · Cited by 4
Cardiovascular benefits of GLP-1RA and SGLT-2i in women with type 2 diabetes
Mishriky, B. M., Cummings, D. M., & Powell, J. R. (2022) · Primary care diabetes · doi:10.1016/j.pcd.2022.03.012 · Cited by 5
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00921-5 · Cited by 8
Eraikhuemen, N., Leung, S., Warren, S. B., Lazaridis, D., Smith, C. H., Kearson, M. L., & Marcellus, V. (2022) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-022-00561-6 · Cited by 5
Zhou, Y., Wang, F., Wen, F.-F., Li, C., & Ye, T.-T. (2023) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2023.2250949 · Cited by 4
“…are shown in (Figures 2–3); this included 3 articles involving Dapagliflozin [1,16,17], 2 articles involving Sotagliflozin [5,18], 1 article involving Bexagliflozin [19], 2 articles involving Canagliflozin [2,20], 3 articles involving Empagliflozin [21–23], and 1 article on Ertugliflozin [24].”
BackgroundHuang, L., Hu, R., & Zou, H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1419729 · Cited by 4
Patoulias, D., Papadopoulos, C. E., Kalogirou, M., Katsimardou, A., Toumpourleka, M., & Doumas, M. N. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.10.001 · Cited by 5
Volpe, M., & Patrono, C. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa891 · Cited by 4
“However, based on previous studies showing positive effects of other SGLT2i on CV and renal outcomes, the VERTIS-CV protocol had been amended to reflect a doubling of the original sample size and inclusion of efficacy objectives for superiority.(1-4) Therefore, the largely negative results of VERTIS-CV are surprising…”
ResultEmerging Pharmacologic Therapies for Heart Failure With Reduced Ejection Fraction
Chaudhary, A., Alreefi, F., & Aziz, M. (2021) · CJC Open · doi:10.1016/j.cjco.2021.01.006 · Cited by 4
Perez-Belmonte, L. M., Ricci, M., Sanz‐Cánovas, J., Cobos-Palacios, L., Lopez-Carmona, M. D., Ruiz-Moreno, M. I., Millán‐Gómez, M., Bernal-López, M. R., Jansen‐Chaparro, S., & Gómez‐Huelgas, R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10092013 · Cited by 4
Estrada, A. K., Delgado‐Maldonado, T., Lara-Ramirez, E. E., Martínez-Vázquez, A. V., Ortíz-Pérez, E., Paz-González, A. D., Bandyopadhyay, D., & Rivera, G. (2021) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557521666210805112416 · Cited by 4
Inhibition of sodium-glucose cotransporter 2 to slow the progression of chronic kidney disease
Oguz, F., Demoulin, N., Thissen, J. P., Jadoul, M. Y., & Morelle, J. (2021) · Acta Clinica Belgica · doi:10.1080/17843286.2021.1966583 · Cited by 5
“lar events among patients with type 2 diabetes and atherosclerotic cardiovascular disease [16].”
BackgroundKobayashi, K., Toyoda, M., Hatori, N., Sato, K., Miyakawa, M., Tamura, K., & Kanamori, A. (2021) · Primary care diabetes · doi:10.1016/j.pcd.2021.08.012 · Cited by 5
Sodium glucose cotransporter 2 inhibitors: New horizon of the heart failure pharmacotherapy
Naito, R., & Kasai, T. (2021) · World Journal of Cardiology · doi:10.4330/wjc.v13.i9.464 · Cited by 4
Georgiou, P., Shi, W., Serhiyenia, T., Akram, A., Proute, M. C., Pradeep, R., Kerolos, M. E., & Khan, S. (2021) · Cureus · doi:10.7759/cureus.18485 · Cited by 4
“The most recent VERTIS-CV trial did not show a cardiovascular benefit in SGLT-2i, and the difference is likely multifactorial.”
BackgroundMethodResultInfluentialJensen, J., Omar, M., Kistorp, C., Gustafsson, F., Køber, L., Møller, J. E., & Schou, M. (2022) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13739 · Cited by 4
“11]).(12) In patients with T2D and chronic kidney disease (CKD), canagliflozin demonstrated reductions in major adverse cardiovascular events (HR 0.”
BackgroundEfficacy of SGLT2 inhibitors in patients with heart failure: An overview of systematic reviews
Sephien, A., Ghobrial, M., Reljic, T., Prida, X. E., Nerella, N. K., & Kumar, A. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.11.052 · Cited by 4
Chen, H., Meng, R., Yang, Y., & Yu, T.-H. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2182290 · Cited by 4
Zhang, J., Spall, H. G. C. V., Li, L., Khan, M. S., Pandey, A., Thabane, L., Bai, X., Wang, Y., Lip, G. Y. H., & Li, G. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102804 · Cited by 4
Combination therapy with kidney protective therapies: optimizing the benefits?
Kotwal, S. S., Perkovic, E., & Perkovic, V. (2023) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000929 · Cited by 4
Block, T. J., & Cooper, M. E. (2023) · La Presse Médicale · doi:10.1016/j.lpm.2023.104178 · Cited by 4
Patoulias, D., Papadopoulos, C. E., Stavropoulos, K., Imprialos, K. P., & Doumas, M. N. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.10.004 · Cited by 4
Kamrul-Hasan, A. B. M., Alam, M. S., Talukder, S. K., Hannan, M. A., Dutta, D., Nagendra, L., & Selim, S. (2024) · Journal of Diabetes Research · doi:10.1155/2024/5553327 · Cited by 4
Cherney, D. Z. I., Frederich, R. C., Pratley, R. E., Cosentino, F., Dagogo-Jack, S. E., Pong, A., Gantz, I., Cater, N. B., Mancuso, J. P., MASIUKIEWICZ, U. S., et al. (2025) · Kidney Diseases · doi:10.1159/000543162 · Cited by 3
Self-citationHave SGLT-2 inhibitors DELIVERed an EMPhatic win in heart failure and chronic kidney disease?
Singh, A. K., Singh, A., & Singh, R. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2464905 · Cited by 5
Cardiovascular-kidney-metabolic syndrome and treatment advances: a narrative review
Peña, C., Flores, J., & NUGENT, K. M. (2025) · Minerva Medica · doi:10.23736/s0026-4806.25.09607-7 · Cited by 6
Nardi, E., Prastaro, M., Santoro, C., Gallo, L., Simeoli, L., Fontanarosa, S., Paolillo, S., Gargiulo, P., Esposito, G., & Filardi, P. P. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104033 · Cited by 3
SGLT2 inhibitors in translational medicine: A paradigm shift for diabetes and heart health
Soni, R., Pal, D., Gupta, A. K., Mishra, A., Vaishnav, Y., & Jain, S. K. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117977 · Cited by 3
Hitting the Sweet Spot: A Review of SGLT2i in Cardiovascular Medicine
Zayyad, Z. A., Gupta, N., Roy, A., Kalagara, S., Mishra, A., Salem, E., Seshadri, S. R., Gichi, D., Hammad, B., Ene, A., et al. (2025) · Cardiology and Therapy · doi:10.1007/s40119-025-00436-2 · Cited by 4
“Similarly, the VERTIS-CV trial confirmed the CV safety of ertugliflozin but showed no significant superiority in MACE outcomes [7].”
Gurgoglione, F. L., Covani, M., Triglia, L. T., Benatti, G., Donelli, D., Bianconcini, M., Solinas, E., Tadonio, I., Denegri, A., Gregorio, M. D., et al. (2025) · Life · doi:10.3390/life15111784 · Cited by 3
“Randomized controlled trials have shown that the benefits of SGLT2i extend beyond glycaemia control, reducing hospitalizations for heart failure [6–9] and lowering both cardiovascular and all-cause mortality [10–13].”
Rao, Y., Meng, S., Yu, E. Y.-W., Chen, Y., van Alebeek, R., Al-Zalabani, A. H., Zeegers, M. P., & Wesselius, A. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.11.017 · Cited by 4
Yu, Z., Gu, B., Zhang, J., Jin, W., Wan, H., & Jin, W. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2025.1721311 · Cited by 3
Beyond safety: adverse events and unanticipated advantages of SGLT2 inhibitors
Falsetti, L., Tarquinio, N., Mucci, L., Santini, S., Guerrieri, E., Giovenali, L., Pierdomenico, G., Zaccone, V., Viticchi, G., & Moroncini, G. (2026) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-026-04023-9 · Cited by 3
“Prevalence − 1.”
Farmakis, D. T., Karampinos, K. I., Kapelios, C. J., Liori, S., Fountoulaki, K., & Filippatos, G. S. (2026) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcag061 · Cited by 3
Stamouli, E., Trakatelli, C., Sarigianni, M., Kitsios, K., & Kotsis, V. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03239-4 · Cited by 3
“The VERTIS CV trial of ertugliflozin demonstrated cardio-vascular safety, with a neutral MACE result, but a significant reduction in heart failure hospitalisation [25].”
Fisher, M. (2021) · British Journal of Diabetes · doi:10.15277/bjd.2021.320 · Cited by 5
Feher, M. D., Hinton, W., Forbes, A., Munro, N. M., Joy, M., Wheeler, D. C., & de Lusignan, S. (2022) · JMIR Research Protocols · doi:10.2196/34206 · Cited by 3
“For the last 2 decades, renin-angiotensin system (RAS) blockade medications (either angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) have been considered—in addition to maximal glucose and blood pressure control—to be part of standard therapy for preventing or delaying the progression of DKD…”
InfluentialImputation of Missing Data for Time-to-Event Endpoints Using Retrieved Dropouts
Wang, S., Frederich, R. C., & Mancuso, J. P. (2023) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-023-00575-5 · Cited by 3
“…hazards model has long been regarded as the gold standard to analyze time to first event endpoints in cardiovascular and renal outcome trials [37, pp. 1425–1435, 38, pp. 896–907, 39, pp. 1436–1446, 40, pp. 841–851, 41, pp. 2295–2306, 5, pp. 1527–1539, 42, pp. 347–357, 43, pp. 2117–2128].”
Self-citationLi, L., Dong, Y.-H., Bai, Y. S., Tang, Z., Deng, Y.-M., Wu, Z., & Li, W. (2023) · Endocrine · doi:10.1007/s12020-023-03618-x · Cited by 4
Piepoli, M. F., Rosano, G. M. C., Abreu, A., Adamo, M., Attanasio, A., Chioncel, O., Solal, A. C., Filippatos, G., Gerdts, E., Gevaert, A. B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehag362 · Cited by 7
Zhang, A., Kalil, R. K., Marzec, A., Coulter, S., Virani, S. S., Patel, K. V., & Segar, M. W. (2024) · Texas Heart Institute Journal · doi:10.14503/thij-23-8375 · Cited by 5
Tiwari, K., Deora, S., Choudhary, R., Kaushik, A., Dwivedi, P., Singh, S., Ambwani, S. R., Midha, N. K., Shukla, R. K. G., Sankanagoudar, S., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-089562 · Cited by 3
“27 Among patients with HF, a network meta-analysis concluded that dapagliflozin decreased maximum CV death when compared with different SGLT2i.”
BackgroundNg, P. Y., Ng, A. K., Ip, A., Sin, W. C., & Yiu, K. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.037207 · Cited by 3
Rossing, P. R., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2481-2004 · Cited by 3
Updates in chronic kidney disease management: A systematic review
Ammar, A., Edwin, S. B., Whitney, R., Lipari, M., & Giuliano, C. A. (2025) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70014 · Cited by 3
“15–18 Although the exact mechanisms of kidney-protective effects of SGLT2i are not fully understood, several proposed mechanisms exist in addition to glucose lowering.”
Ha, K. H., Park, M., Lee, Y., Kim, D. J., & Han, S. J. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101668 · Cited by 3
Schechter, M., Cohen, Y., Fishkin, A., Mosenzon, O., Leibowitz, G., & Aharon‐Hananel, G. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112338 · Cited by 3
Jamil, S., Zainab, A., Arora, A. K. M. S., Shaik, T. A., Khemani, V., Mekowulu, F. C., Aschalew, Y. N., & Khan, S. (2022) · Cureus · doi:10.7759/cureus.31898 · Cited by 6
“[15] 2020 Multicenter Stage 3 SGLT2 Ertugliflozin 1199 42 months 68.”
BackgroundInfluentialBesmaya, B. M., & Laksono, S. (2023) · MPI (Media Pharmaceutica Indonesiana) · doi:10.24123/mpi.v5i1.5266 · Cited by 7
“Beberapa studi yang dimaksud (CANVAS, EMPA-REG, DECLARE-TIMI 58, VERTIS-CV) menyimpulkan bahwa SGLT-2 lebih unggul daripada plasebo dalam menurunkan risiko kejadian kardiovaskular dan mortalitas kardiovaskular serta meningkatkan kontrol glikemik pada penderita PKV dan DM. Namun demikian, mekanisme aksi yang digunakan…”
InfluentialDing, Q., Spatz, E. S., Bena, J., Morrison, S. L., Levay, M., Lin, H., Grey, M. J., Edwards, N. E., Isaacs, D. M., West, L. M., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.029058 · Cited by 4
Diabetic status aggravates atherosclerosis in aged A po E −/− mice
Yu, Q., Tian, K., Fatima, N., & Zhao, S. (2023) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12375 · Cited by 3
Lalic, N. M., Jotić, A., Lukić, L., Milicic, T. J., Macesic, M. V., Gajović, J. S., Stoiljkovic, M. M., Milovancevic, M. M., Cvetković, D. R., & Lalic, K. S. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111816 · Cited by 3
Long‐term weight loss and cardiorenal outcomes by baseline BMI in the VERTIS CV trial
Cosentino, F., Dagogo-Jack, S. E., Frederich, R. C., Cannon, C. P., Cherney, D. Z. I., Mancuso, J. P., Wynant, W., Xing, A., Gantz, I., Cater, N. B., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16050 · Cited by 4
Self-citationPandey, A., Kolkailah, A. A., McGuire, D. K., Frederich, R. C., Cater, N. B., Cosentino, F., Pratley, R. E., Dagogo-Jack, S. E., Cherney, D. Z. I., Wynant, W., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3511 · Cited by 3
“5,6 HHF. 5,6 Furthermore, ertugliflozin treatment reduced the risk of peripheral oedema, a common sign of HF.”
InfluentialSelf-citation
Metadata
- Authors
- Cannon, C. P., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Masiukiewicz, U., Charbonnel, B., Frederich, R., Gallo, S., Cosentino, F., Shih, W. J., Gantz, I., Terra, S. G., Cherney, D. Z. I., & McGuire, D. K.
- Affiliations
- Rutgers, The State University of New Jersey (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-10-08
- Volume
- 383
- Issue
- 15
- Pages
- 1425-1435
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3089283105
- Cited by
- 1,514
- References
- 14
- Citations by year
- 2026: 126 · 2025: 177 · 2024: 231 · 2023: 269 · 2022: 298 · 2021: 364 · 2020: 47
- FWCI
- 184.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Pfizer
- Merck
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- ertugliflozin, SGLT2 inhibitors, type 2 diabetes, atherosclerotic cardiovascular disease, major adverse cardiovascular events, heart failure hospitalization, cardiovascular mortality, non-inferiority, renal safety, non-inferiority margin, myocardial infarction, stroke, renal replacement therapy, serum creatinine doubling, cardiovascular risk stratification
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Female, Hospitalization, Humans, Male, Middle Aged, Placebos, Bridged Bicyclo Compounds, Heterocyclic, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.